CN Patent

CN104640861A — 作为激酶抑制剂的嘌呤酮化合物

Assigned to Pharmacyclics LLC · Expires 2015-05-20 · 11y expired

What this patent protects

本文公开了与布鲁顿酪氨酸激酶(Btk)形成共价键的化合物。还描述了Btk的不可逆抑制剂。另外，还描述了Btk的可逆抑制剂。还公开了包含该化合物的药物组合物。公开了单独地或与其它治疗剂联合地使用该Btk抑制剂治疗自身免疫疾病或状况、异种免疫疾病或状况、包括淋巴瘤在内的癌症和炎性疾病或状况的方法。

USPTO Abstract

本文公开了与布鲁顿酪氨酸激酶(Btk)形成共价键的化合物。还描述了Btk的不可逆抑制剂。另外，还描述了Btk的可逆抑制剂。还公开了包含该化合物的药物组合物。公开了单独地或与其它治疗剂联合地使用该Btk抑制剂治疗自身免疫疾病或状况、异种免疫疾病或状况、包括淋巴瘤在内的癌症和炎性疾病或状况的方法。

Drugs covered by this patent

Wayrilz (RILZABRUTINIB) · Genzyme Corp

Patent Metadata

Patent number: CN104640861A
Jurisdiction: CN
Classification: —
Expires: 2015-05-20
Drug substance claim: No
Drug product claim: No
Assignee: Pharmacyclics LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.